Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HDAC
Biotech
Cereno's HDAC inhibitor reduces risks from PAH in phase 2 trial
Cereno Scientific’s hypertension drug was shown to improve the risk score of 43% of patients in a phase 2 study.
James Waldron
Sep 30, 2024 9:35am
A SMRT new target for male contraceptives works in mice
Feb 22, 2024 3:35pm
Homing in on one HDAC sees early success in a lung cancer
Mar 20, 2023 11:54am
Could inhibiting both HDAC and PD-1 improve I-O treatments?
Jun 24, 2019 10:30am
Viracta's combo garners high response in EBV-linked lymphoma
Jun 3, 2019 11:39am
Xynomic preps broad push for HDAC cancer drug
Jun 1, 2018 10:26am
